72F fusion protein vaccine
72F fusion protein vaccine is a candidate tuberculosis vaccine created by Statens Serum Institut (SSI). The 72F fusion protein is composed of the Rv0125 and Rv1196 proteins derived from Mycobacterium tuberculosis. Phase I clinical trials were completed in 2005 and Phase II trials are awaited.
- Kaufmann SHE, McMichael AJ (2005). "Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis". Nature Medicine 11 (4 suppl): S33–S44. doi:10.1038/nm1221. PMID 15812488. Retrieved 2006-04-30.
|This immunology article is a stub. You can help Wikipedia by expanding it.|